Pennsylvania saw a meteoric rise in the number of adolescents receiving puberty blockers through an insurance billing code currently being investigated under the Trump administration on fraud […] ...
Pennsylvania saw a meteoric rise in the number of adolescents receiving puberty blockers through an insurance billing code currently being ...
Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients with central precocious puberty (CPP), potentially opening the door | ...
MedPage Today on MSN
GLP-1 Drug Market Changes; Wegovy Pill Hits Shelves; Hypercortisolism Drug Rejected
And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide ...
In return for $10 million upfront, Foresee sold the global rights for its MMP-12 inhibitor programs to Primevera Therapeutics ...
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced, following approval at its 2025 Extraordinary General Shareholders' Meeting, that Foresee Pharmaceuticals USA Inc., the Company's ...
Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.Foresee will receive a 10 million USD upfront payment, potential milestones of ...
Three of the world’s top trans healthcare organisations have expressed “significant ethical concerns” regarding the UK ...
The Government is intent on “moving away” from medical interventions for transgender young people, a minister has suggested.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback